Roberts syndrome fibroblasts showing cisplatin hypersensitivity have normal host cell reactivation of cisplatin-treated adenovirus and normal capacity of cisplatin-treated cells for adenovirus DNA synthesis

被引:3
作者
Davis, K
Tomkins, DJ
Rainbow, AJ
机构
[1] MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4K1,CANADA
[2] MCMASTER UNIV,DEPT PEDIAT,HAMILTON,ON L8S 4K1,CANADA
[3] MCMASTER UNIV,DEPT RADIOL,HAMILTON,ON L8S 4K1,CANADA
关键词
D O I
10.1007/BF02369895
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Roberts syndrome (RS) is a rare, recessively inherited disorder characterized by growth retardation, limb reductions and craniofacial deformities. Cells from a subset of afflicted individuals, termed RS(+), display unusual separation or puffing of the heterochromatic regions of their chromosomes and are hypersensitive to sever-al DNA-damaging agents including mitomycin C (MMC) and cisplatin, both of which can induce interstrand crosslinks in DNA. For this reason, we have investigated the ability of RS(+) fibroblasts to repair cisplatin-induced DNA lesions using adenovirus as a probe. Host cell reactivation of cisplatin-treated adenovirus (Ad) was significantly reduced in nucleotide excision repair (NER)-deficient xeroderma pigmentosum (XP) cells but was normal in the two RS(+) fibroblast strains and the Fanconi's anemia (FA) fibroblast strain tested. The capacity of cisplatin-treated cells for Ad DNA synthesis was reduced in XP and FA cells compared to normal human cells, but was not reduced in RS(+) cells. These results indicate that the hypersensitivity of RS(+) cells to cisplatin is not due to a deficiency in NER nor due to a deficiency in the pathway which leads to cisplatin hypersensitivity in FA cells. It is possible that the abnormal heterochromatin organisation of RS(+) cells selectively renders the heterochromatic regions of the genome more susceptible to mutagen damage and/or less available for repair.
引用
收藏
页码:393 / 402
页数:10
相关论文
共 57 条
[22]  
GANI R, 1984, AM J HUM GENET S, V37, pA9
[23]  
GENTNER N E, 1985, American Journal of Human Genetics, V37, pA231
[24]  
Gentner NE., 1986, P CAN FED BIOL SCI, V29, P144
[25]  
GERMAN J, 1972, PROG MED GENET, V8, P61
[26]  
GERMAN J, 1979, CLIN GENET, V16, P441
[27]  
GRUENERT DC, 1985, CANCER RES, V45, P5399
[28]   A DAMAGE-RECOGNITION PROTEIN WHICH BINDS TO DNA CONTAINING INTERSTRAND CROSS-LINKS IS ABSENT OR DEFECTIVE IN FANCONI-ANEMIA, COMPLEMENTATION GROUP-A, CELLS [J].
HANG, B ;
YEUNG, AT ;
LAMBERT, MW .
NUCLEIC ACIDS RESEARCH, 1993, 21 (18) :4187-4192
[29]  
HANSSON J, 1991, CANCER RES, V51, P3384
[30]  
HITT M, 1995, METH MOL G, V7, P13